Biogen (BIIB) is scheduled to resume trading at 3:05 p.m. ET, with quotation set to resume at 3:00 p.m. ET, according to Nasdaq. Shares were halted, pending news, ahead of the company and partner Eisai (ESALY) announcing that the U.S. Food and Drug Administration has approved lecanemab-irmb, U.S. brand name Leqembi, for the treatment of Alzheimer’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen, Eisai May Have an Alzheimer’s Beater on Their Hands
- RBC says hotline sign of possible imminent approval for Biogen
- Needham health/pharmaceuticals analysts hold analyst/industry conference call
- Biogen promotes Singhal to EVP, Head of Development
- Biogen Names Priya Singhal as Executive Vice President, Head of Development